Comparative study reveals major delays in Lu-PSMA therapy access in Brazil compared to Europe, highlighting the need to strengthen radiopharmaceutical supply chains.
Lu-PSMA therapy is nearly 3 times slower in Brazil than in Europe. Closing the therapeutic access gap requires targeted investments in radiopharmaceutical supply chains and regulatory efficiency.
No takes yet. Share an insight, caveat, or question.
Cerci et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: